Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845152 | 1.00 | CHRM2 (0.32) | CHRM2CHRM1KCNH2CYP2D6S1PR1 | |
| SCHEMBL1846153 | 0.80 | CYP2D6 (0.39) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL1846177 | 0.80 | CYP2D6 (0.39) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL3230261 | 0.77 | RAB9A (0.35) | CHRM2CHRM1KCNH2CYP2D6POLB | |
| SCHEMBL3230254 | 0.77 | RAB9A (0.35) | CHRM2CHRM1KCNH2CYP2D6POLB | |
| SCHEMBL14291856 | 0.68 | CHRM3 (0.39) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL4728734 | 0.68 | POLB (0.41) | CHRM2CHRM1KCNH2CYP2D6POLB | |
| SCHEMBL20176049 | 0.63 | MEN1 (0.36) | CHRM2CHRM1KCNH2CYP2D6POLB | |
| SCHEMBL1315214 | 0.62 | KEAP1 (0.44) | CHRM2CHRM1KCNH2CYP2D6POLB | |
| SCHEMBL9809488 | 0.62 | KEAP1 (0.46) | CHRM2CHRM1KCNH2POLBCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245292-A1 | 2-HYDROXY-ETHANESULFONATE SALT | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| EP-2323655-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323656-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323653-A1 | 2-HYDROXY-ETHANESULFONATE SALT | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019097-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018352-A1 | HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019099-A1 | 2-HYDROXY-ETHANESULFONATE SALT | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019098-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | CHRM2 11/4885CHRM1 21/4885KCNH2 233/4885 |
| US-20110245292-A1 | 2-HYDROXY-ETHANESULFONATE SALT | CHRM3, CHRM2, CHRM5 | CHRM2 2/4885CHRM1 5/4885KCNH2 101/4885 |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | GRK5, GRK2, GRK4 | CHRM2 14/4885CHRM1 34/4885KCNH2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.